Search results
Results from the WOW.Com Content Network
Epoetin alfa, sold under the brand name Epogen among others, is a human erythropoietin produced in cell culture using recombinant DNA technology. [ 8 ] [ 9 ] Epoetin alfa is an erythropoiesis-stimulating agent. [ 8 ]
n/a n/a Ensembl n/a n/a UniProt n a n/a RefSeq (mRNA) n/a n/a RefSeq (protein) n/a n/a Location (UCSC) n/a n/a PubMed search n/a n/a Wikidata View/Edit Human Erythropoietin (/ ɪ ˌ r ɪ θ r oʊ ˈ p ɔɪ. ɪ t ɪ n, - r ə -, - p ɔɪ ˈ ɛ t ɪ n, - ˈ iː t ɪ n / ; EPO), also known as erythropoetin, haematopoietin, or haemopoietin, is a glycoprotein cytokine secreted mainly by the kidneys ...
They were first approved for medical use in the United States in 1989. [5] It is on the World Health Organization's List of Essential Medicines. [7] Commercially available agents include epoetin alfa and darbepoetin alfa, and biosimilars. [1] [2] Use among athletes is prohibited by the World Anti-Doping Agency. [5]
For years, biotech company Amgen (NAS: AMGN) has dominated the anemia market with its blockbuster drug, Epogen. The product has scored billions of dollars for the company and rewarded shareholders ...
At the end of last year, I proclaimed Omontys -- an erythropoiesis-stimulating agent, or ESA, that aids in the formation of red blood cells -- as one of my 10 drugs approved by the Food and Drug ...
Epoetin beta (), sold under the brand name Neorecormon among others, is a synthetic, recombinant [4] form of erythropoietin, a protein that promotes the production of red blood cells.
Affymax received its first Food and Drug Administration approval last spring with Omontys for anemia in dialysis patients. The drug enters a war against Amgen's Epogen, which has held a near ...
In response to these advisories, the FDA released a Public Health Advisory [14] on 9 March 2007, and a clinical alert [15] for doctors on 16 February 2007, about the use of erythropoeisis-stimulating agents (ESAs) such as epoetin alfa (marketed as Epogen) and darbepoetin alfa. The advisory recommended caution in using these agents in cancer ...